Immune therapy: a new therapy for acute myeloid leukemia
Although complete remission could be achieved in about 60%–70% of acute myeloid leukemia (AML) patients after conventional chemotherapy, relapse and the state of being refractory to treatment remain the main cause of death. In addition, there is a great need for less intensive regimens for all medic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2023-03-01
|
| Series: | Blood Science |
| Online Access: | http://journals.lww.com/10.1097/BS9.0000000000000140 |